This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
Name9-aminocamptothecin
Accession NumberDB12515
TypeSmall Molecule
GroupsInvestigational
Description

Aminocamptothecin has been used in trials studying the treatment of Lymphoma, Gastric Cancer, Ovarian Cancer, Esophageal Cancer, and Ovarian Neoplasms, among others.

Structure
Thumb
Synonyms
Aminocamptothecin
External IDs NSC-603071
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII5MB77ICE2Q
CAS number91421-43-1
WeightAverage: 363.373
Monoisotopic: 363.121906039
Chemical FormulaC20H17N3O4
InChI KeyFUXVKZWTXQUGMW-FQEVSTJZSA-N
InChI
InChI=1S/C20H17N3O4/c1-2-20(26)13-7-16-17-10(6-11-14(21)4-3-5-15(11)22-17)8-23(16)18(24)12(13)9-27-19(20)25/h3-7,26H,2,8-9,21H2,1H3/t20-/m0/s1
IUPAC Name
(19S)-8-amino-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione
SMILES
CC[[email protected]@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC=C(N)C1=C3)C2=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Aminocamptothecin.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Aminocamptothecin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aminocamptothecin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Aminocamptothecin.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Aminocamptothecin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Aminocamptothecin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Aminocamptothecin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aminocamptothecin.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Aminocamptothecin.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Aminocamptothecin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aminocamptothecin.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Aminocamptothecin.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemia, Myelocytic, Acute1
2CompletedTreatmentCancer, Ovarian1
2CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2CompletedTreatmentMalignant Lymphomas2
2CompletedTreatmentNeoplasms, Ovarian1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.633 mg/mLALOGPS
logP1.35ALOGPS
logP0.39ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)11.71ChemAxon
pKa (Strongest Basic)3.91ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area105.75 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity99.19 m3·mol-1ChemAxon
Polarizability37.87 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring).
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassCamptothecins
Sub ClassNot Available
Direct ParentCamptothecins
Alternative ParentsAminoquinolines and derivatives / Pyranopyridines / Pyridinones / Benzenoids / Tertiary alcohols / Heteroaromatic compounds / Amino acids and derivatives / Carboxylic acid esters / Lactones / Lactams
SubstituentsCamptothecin / Aminoquinoline / Pyranopyridine / Quinoline / Pyridinone / Pyridine / Benzenoid / Heteroaromatic compound / Tertiary alcohol / Amino acid or derivatives
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorspyranoindolizinoquinoline (CHEBI:80755 )
Drug created on October 20, 2016 16:40 / Updated on September 01, 2017 12:21